Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 11.4% | -2.7% | -4.7% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| -4.7% | 11.4% | 26.6% | -29.5% | 16.6% | 30.9% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 11.4% | -2.7% | -4.7% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| -4.7% | 11.4% | 26.6% | -29.5% | 16.6% | 30.9% |
Conestoga's SMid Cap Composite returned -2.71% net in Q4 2025, trailing the Russell 2500 Growth Index's 0.33% return, bringing full-year performance to -4.71% versus the benchmark's 10.31%. The year was characterized by extreme market volatility and narrow leadership, with low-quality, unprofitable stocks dominating returns during the April-October rally that saw the Russell 2000 Growth Index surge nearly 50%. However, profitable stocks began outperforming from mid-October through year-end, suggesting a potential shift back to quality leadership. Small Cap biotechnology and pharmaceuticals drove 132% of Q4 index returns, while the firm's underweight positioning in these volatile sectors created headwinds. Looking forward, Conestoga sees a compelling opportunity for Small Caps, which are projected to achieve 32% earnings growth in 2026 versus 13% for Large Caps, while trading at a 25% discount. The firm believes pro-growth government policies and improving fundamentals could herald a new extended cycle of Small Cap outperformance for the first time since 2020.
Conestoga believes Small Cap stocks are positioned for a new cycle of outperformance driven by superior earnings growth prospects, attractive valuations relative to Large Caps, and supportive policy tailwinds, while maintaining focus on high-quality companies as market leadership transitions away from speculative low-quality stocks.
Looking ahead we think the outlook for Small Cap stocks is bright. After experiencing two years of negative earnings growth, Small Caps achieved nearly 9% earnings growth in 2025 and are projected to grow by an additional 32% in 2026. Given the anticipated economic growth tailwinds from last year's pro-growth and deregulatory government policies, we believe there is a compelling case for Small Caps to outperform Large Caps for the first time since 2020. This could potentially herald a new, extended cycle of Small Cap outperformance.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 18 2026 | 2025 Q4 | AAON, AZTA, BCPC, BLFS, BMI, BSY, BWMN, COCO, CPRT, CSGP, CSW, CWAN, CWST, CYX, DGII, DSGX, ELVA, ESE, FSV, GNRC, GWRE, HEI.A, IDXX, IIIV, IRMD, IT, JKHY, KRMN, LMAT, MAMA, MEG, MLAB, MMSI, NGEN, NOVT, ODD, OLO, PHR, PL, PLMR, POOL, QTWO, RBC, RGEN, ROAD, ROL, ROP, SPSC, SSTI, STVN, TKNO, TREX, TRNS, TYL, UTI, VCEL, VEEV, VERX, VRSK, WCN, WLDN, WSO, WST | Biotechnology, defense, growth, industrials, Quality, small caps, technology |
RGEN RBC JKHY CSW CWAN FSV POOL TREX STVN ROAD AAON KRMN GNRC |
Small Caps achieved nearly 9% earnings growth in 2025 and are projected to grow by an additional 32% in 2026, contrasting with 13% growth expected for Large Caps. Small Caps are trading at a nearly 25% discount to Large Caps, creating a compelling case for outperformance for the first time since 2020. The market experienced extreme leadership concentrated in low-quality, high-beta, unprofitable stocks during the April-October rally. However, profitable stocks began outperforming unprofitable counterparts by over 5% from mid-October through year-end, suggesting high-quality stocks may be reclaiming leadership. Small Cap Biotech/Pharmaceutical stocks represented 132% of the Russell 2000 Growth Index's total returns in the fourth quarter alone, after comprising just 11% through the third quarter. The bioprocessing market showed clear signs of recovery with companies delivering encouraging order growth. Defense technology companies specializing in highly engineered, mission-critical systems showed strong performance. Companies with exposure to space, missiles, hypersonic, and defense programs generated mid-teens organic revenue growth complemented by acquisitions. |
| Oct 13 2025 | 2025 Q3 | CWST, DSGX, EVI, GNRC, JKHY, MRCY, QTWO, ROAD, TYL, WST | quality growth, semiconductors, SMID Caps, software, technology | - | The SMid-Cap strategy underperformed amid a rally dominated by unprofitable, high-beta stocks, while its disciplined quality-growth approach faced headwinds. Weakness in software and lack of semiconductor exposure weighed on returns, though select industrials and healthcare names showed resilience. Management views the current low-quality outperformance as typical of early-cycle conditions likely to normalize. |
| Jul 22 2025 | 2025 Q2 | AXON, CWAN, EXPO, FICO, GWRE, HEI, MMSI, NEOG, POOL, RBC, ROAD, WSO | cash flow, fundamentals, growth, SMID Caps, valuation |
ROAD AXON GWRE RBC |
The letter emphasizes disciplined growth investing amid tariff uncertainty and rapid market rebounds. While narrow leadership hurt short-term performance, management remains focused on companies with scalable business models and consistent cash generation. SMid-cap growth is viewed as attractive as valuation gaps persist. |
| May 1 2025 | 2025 Q1 | ALTR MM, BFAM, CCCS, HBCP, IT, MMSI, PCTY, QTWO, ROAD, ROL, SPSC, WK | - | - | |
| Dec 31 2024 | 2024 Q4 | AXON, BFAM, CGNX, DSGX, EXPO, HLMN, KAI, MTN, NCNO, NOVT, PCOR, QTWO, ROAD, TFX, WK | - | - | |
| Oct 23 2024 | 2024 Q3 | ALTR, AXON, CGNX, EXPO, FIVN, FSV, GWRE, MSA, ROAD, TREX, WST | - | - | |
| Jun 30 2024 | 2024 Q2 | EXPO, FICO, GWRE, HEI, POOL, RGEN, SITE, STVN, TREX, TYL | - | - | |
| Apr 15 2024 | 2024 Q1 | AXON, BFAM, CWST, FIVN, MRCY, NEOG, ROAD, TREX, WK | - | - | |
| Dec 31 2023 | 2023 Q4 | CCCS, FICO, IT, JBT, MSA, PYCR, ROAD, SITE, SSD, STVN, TREX, WST | - | - | |
| Sep 30 2023 | 2023 Q3 | CSWI, CWAN, CWST, FICO, GGG, GWRE, MMSI, NOVT, OMCL, RGEN, ROAD, ROL | - | - | |
| Jun 30 2023 | 2023 Q2 | AXON, EXPO, FICO, GGG, MRCY, PLOW, RBC, RGEN, SPSC, TREX, WSO | - | - | |
| May 23 2023 | 2023 Q1 | ALTR, AXON, CWAN, FICO, JKHY, LSPD, PLOW, TECH, WSR | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
DefenseThe team initiated a position in Curtiss-Wright, believing the company is entering a period where multiple near-term growth drivers are converging, including rising defense budgets, commercial aerospace production ramps, nuclear power plant life extensions and new builds, and submarine production. |
Defense Budgets Aerospace Nuclear Submarines |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position | |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
TechnologyHoldings span social media, online search, cloud computing and e-commerce including select Magnificent 7 positions. They also own semiconductor companies at reasonable valuations, including picks and shovels businesses like Applied Materials with strong competitive positions and long track records of value creation. |
Technology Semiconductors Cloud Social Media E-commerce | |
| 2025 Q3 |
SMID Caps |
|
Technology |
||
| 2025 Q2 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 18, 2026 | Fund Letters | Bob Mitchell | RGEN | Repligen Corp. | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | biologics, Bioprocessing, Consumables, Destocking, operating leverage | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | RBC | RBC Bearings, Inc. | Industrials | Aerospace & Defense | Bull | New York Stock Exchange | Aerospace, Defense, Freecashflow, Margins, operating leverage | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | JKHY | Jack Henry & Associates, Inc. | Information Technology | Application Software | Bull | NASDAQ | Corebanking, financial software, Modernization, Recurringrevenue, stability | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | CSW | CSW Industrials, Inc. | Industrials | Industrial Machinery | Bull | NASDAQ | Acquisitions, aftermarket, capital allocation, HVAC, Industrials | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | CWAN | Clearwater Analytics Holdings, Inc. | Information Technology | Application Software | Bull | New York Stock Exchange | acquisition, analytics, recurring revenue, Software, switching costs | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | FSV | FirstService Corp. | Real Estate | Real Estate Services | Bear | NASDAQ | Margins, organic growth, Property-services, recurring revenue | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | POOL | Pool Corp. | Industrials | Trading Companies & Distributors | Bear | NASDAQ | cashflow, Discretionary, Distribution, housing cycle, Pricing pressure | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | TREX | Trex Co., Inc. | Industrials | Building Products | Bear | New York Stock Exchange | Building Products, Competition, Cyclicality, Housing, Margins | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | STVN | Stevanato Group SpA | Health Care | Health Care Supplies | Bear | New York Stock Exchange | execution risk, Glp1, Injectables, Margins, pharmaceuticals | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | ROAD | Construction Partners, Inc. | Industrials | Construction & Engineering | Bear | NASDAQ | backlog, Execution, infrastructure, Margins | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | AAON | AAON, Inc. | Industrials | Building Products | Bear | NASDAQ | datacenters, Executionrisk, HVAC, Industrials, Margins | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | KRMN | Karman Holdings, Inc. | Industrials | Aerospace & Defense | Bull | - | Aerospace, Defense, growth, Ip, Solesource | Login |
| Jul 22, 2025 | Fund Letters | Bob Mitchell | ROAD | Construction Partners, Inc. | Industrials | Construction & Engineering | Bull | NASDAQ | backlog, construction, Funding, infrastructure, Margins | Login |
| Jan 18, 2026 | Fund Letters | Bob Mitchell | GNRC | Generac Holdings, Inc. | Industrials | Electrical Equipment | Bear | New York Stock Exchange | Cyclicality, Energyresilience, Housing, Margins, Powergeneration | Login |
| Jul 22, 2025 | Fund Letters | Bob Mitchell | AXON | Axon Enterprise, Inc. | Industrials | Aerospace & Defense | Bull | NASDAQ | AI, Automation, growth, Publicsafety, Software | Login |
| Jul 22, 2025 | Fund Letters | Bob Mitchell | GWRE | Guidewire Software, Inc. | Information Technology | Systems Software | Bull | NYSE | Bookings, cloud, Insurance, Margins, SaaS | Login |
| Jul 22, 2025 | Fund Letters | Bob Mitchell | RBC | RBC Bearings, Inc. | Consumer Discretionary | Industrial Machinery | Bull | NYSE | Aerospace, Bearings, Industrial, Margins, Quality | Login |
| TICKER | COMMENTARY |
|---|---|
| AAON | AAON declined after the company reported operational challenges related to a recent system rollout. |
| AZTA | but it was outweighed by weakness in Vericel Corp. (VCEL), Neogen Corp. (NGEN), and Azenta, Inc. (AZTA). |
| BMI | BMI is a leading provider of water meters and connected smart-metering solutions primarily for municipal water utilities. The company exhibits hallmarks of high quality, operating in an oligopolistic water-metering market providing must-have solutions, replacement-driven recurring revenue, healthy capital structure, and good management. |
| BSY | BSY provides infrastructure engineering software used in the design and operation of transportation, utilities, and industrial assets. The stock traded lower as revenue growth decelerated modestly and margins were affected by increased investment in product development and go-to-market initiatives. |
| BWMN | BWMN provides multi-disciplinary engineering, planning, and consulting services to the built environment. Shares retraced gains in the fourth quarter after the company reported third-quarter revenue that significantly missed consensus estimates, despite an earnings beat. The revenue shortfall, combined with subsequent insider selling activity in December, contributed to negative sentiment. Bowman Consulting Group, Ltd. (BWMN) also suffered after reporting weaker-than-expected third quarter revenue results which weighed on investor sentiment in what had been a strong year-to-date performer. |
| COCO | Coconut beverage producer Vita Coco returned nearly +25% for the quarter on better-than-expected earnings and reduced concerns around potential tariff risks. |
| CPRT | we recently trimmed some of our mega-cap tech holdings and other outperformers and used the proceeds to buy more of our underperforming holdings such as Copart, Inc. |
| CSGP | The shares of CoStar Group, Inc., the global leader in digitizing real estate, declined in the fourth quarter, due to concerns that the company's residential Homes.com platform will continue to require significant capital investment and competitive worries that Google's new real estate advertisement format and Zillow's OpenAI partnership could divert traffic from Homes.com in the years ahead. |
| CSW | CSW Industrials, Inc. (CSW) is a diversified industrial growth company focused on niche, value added products across three segments: Contractor Solutions, Specialized Reliability Solutions, and Engineered Building Solutions. The portfolio is oriented around products that help customers do the job faster, avoid failures, and protect expensive assets—with core end markets spanning HVAC/R, plumbing, electrical, architecturally-specified building products, and industrial reliability. The core business is Contractor Solutions (~72% of TTM revenue, ~84% of Adj. EBITDA), which sells a broad set of replacement parts, installation accessories, and maintenance and repair tools predominantly used by residential and commercial HVAC and plumbing contractors. Products include HVAC motors and capacitors, evaporator coils, air handlers, condensate pads, pans, pumps, line-set covers, thread sealants, and maintenance chemicals – supported by well-known brands such as RectorSeal, Aspen, MARS, and others. Contractors often ask for CSW products by name and have been using the brands for many years, resulting in pricing power for CSW. Also, management has successfully executed an acquisition playbook in this segment, adding products which immediately benefit from gaining broader distribution through CSW's distribution network. |
| CWAN | With Clearwater, the market was overly focused on the debt and large acquisitions while missing how core Clearwater was growing strongly still and had a tailwind from rate cuts. Clearwater Analytics ended getting bought out and would've netted me a large gain but in the meantime due to the size of the position I took and the options leverage, the weak performance was causing me to question my conviction until I decided to sell my position for a 30% loss, 2 weeks before the buyout news came through. |
| CWST | The fortunes of Casella Waste Systems waxed and waned during the quarter. At the beginning of the quarter, Casella's shares slipped ahead of its fiscal quarterly report. After showing revenues and earnings higher than anticipated, along with better full-year guidance, its share price recovered and ended the quarter up 3% for this provider of solid waste collection, transfer, disposal, and recycling services for residential, commercial, municipal, and industrial customers. |
| DGII | DGII provides connectivity solutions, including routers, gateways, and embedded systems. The stock performed well in the quarter as recurring services revenue grew faster than expected and margins expanded with mix shift toward software and subscriptions. Improved demand visibility in industrial and infrastructure end markets, along with disciplined expense management, supported earnings upside. |
| DSGX | In terms of full year performance effects, stock selection was most challenging in Technology, where fears of the AI eating Software theme gripped the market and caused significant multiple contraction across the group, with SPS Commerce, Inc. (SPSC), Vertex, Inc. (VERX), and Descartes Systems Group, Inc. (DSGX) experiencing the largest negative effects in our portfolio. |
| ELVA | ELVA designs and manufactures lithium-ion battery systems for industrial mobility and energy storage applications. Shares traded higher as order activity strengthened and progress toward commercial scale improved revenue visibility. Advancements in customer adoption and manufacturing execution supported optimism around future growth. The market responded positively to their differentiated battery technology and increasing exposure to electrification trends across material handling and industrial end markets. |
| FSV | Our lone position in Real Estate during the fourth quarter, FirstService, was the portfolio's largest negative contributor. The company specializes in residential management and storm restoration, but it struggled following a soft Q3, as its newly acquired commercial roofing business experienced a slower than expected conversion of its backlog. Additionally, certain large projects have been on hold following a volatile macro environment. This has been happening for several quarters, and the lack of progress has been disappointing. We expect growth to bottom in Q4 and then pick back up, driven by expansion in its remaining business lines. |
| GNRC | Generac Holdings, Inc. (GNRC) was a bottom performer in the SMID Cap strategy in the fourth quarter. Generac's most profitable product group is Home Standby (HSB) generators, and in 2025, the U.S. experienced the fewest power outages (related to weather or other grid failures) since 2015. The lower demand for HSB will also create slightly lower margins for the year. The Commercial and Industrial segment is doing well with sales increasing 9% over last year. |
| GWRE | Shares of P&C insurance software vendor Guidewire Software, Inc. declined during the quarter following strong gains earlier in the year, as the broader software sector came under pressure. After a multi-year transition period, we think Guidewire's cloud migration is largely complete. We believe cloud will be the sole path forward, with annual recurring revenue benefiting from new customer wins and migrations of existing customers to InsuranceSuite Cloud. |
| HEI.A | HEICO Corp. (HEI.A), IDEXX Laboratories, Inc. (IDXX) and Rollins, Inc. (ROL) were the three largest contributors to portfolio returns for the year. |
| IDXX | Veterinary diagnostics leader IDEXX Laboratories, Inc. contributed to performance after again reporting better-than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains modestly negative but is poised to recover over the next several years. Even so, IDEXX's excellent execution has enabled the company to continue delivering robust performance. |
| IIIV | IIIV delivers integrated software and payment solutions to the public sector and healthcare markets. The stock faced pressure during the quarter after management issued a conservative growth forecast for fiscal 2026. The company cited timing delays in project implementations within its utilities and transportation verticals as a primary factor. i3 Verticals, Inc. (IIIV) sagged after providing lower than expected near-term guidance in their quarterly results, but we believe the longer-term outlook remains bright given their positioning for strong recurring revenue growth. |
| IRMD | IRMD develops, manufactures, and markets MRI-compatible medical devices, including infusion pump systems and patient monitors. The company delivered record third-quarter revenue and earnings, prompting management to raise full-year guidance. This strong operational performance, combined with the announcement of a special cash dividend, underscored the company's financial health and commitment to shareholder returns. |
| IT | Gartner is a global leader in research services, with a long history of delivering valuable insights and data to business and technology leaders. In our view, the company has the best brand in IT research, supported by its scale and a compelling customer value proposition. These advantages have driven a long history of strong organic growth and robust free-cash-flow conversion. The stock price has declined meaningfully from recent highs due to investor concerns surrounding AI-related disruption. We believe these concerns are overstated. In our view, Gartner is well-positioned to reaccelerate organic growth due to continued high customer engagement and the large opportunity to sell to new and existing customers. We took advantage of the opportunity to buy shares in this well-managed company at a bargain price. |
| JKHY | Jack Henry & Associates, Inc. is a leading provider of technology solutions for community banks and credit unions. Shares rose after the company reported better-than-expected quarterly results and raised financial guidance. Adjusted revenue grew 9% and earnings per share increased 21% in the quarter, reflecting a favorable demand environment, market share gains, and strong margin expansion. |
| KRMN | KRMN is a defense technology company specializing in the design and manufacturing of highly engineered, mission-critical systems for a diverse set of existing and next-generation space, missiles, hypersonic, and defense programs. KRMN generates mid-teens or better organic revenue growth that is complimented by tuck-in M&A. |
| LMAT | while Stevanato Group SpA (STVN) and LeMaitre Vascular, Inc. (LMAT) were the detractors. |
| MAMA | stocks scaling very nicely and entering the small-cap sweet spot (REAL, MAMA, CBLL, KRMD). |
| NGEN | but it was outweighed by weakness in Vericel Corp. (VCEL), Neogen Corp. (NGEN), and Azenta, Inc. (AZTA). |
| NOVT | Novanta (NOVT) supplies proprietary precision components and systems used in mission-critical medical and advanced industrial applications. |
| ODD | ODD is a consumer technology platform built to transform the global beauty and wellness industry. ODD builds and scales digital-first brands with artificial intelligence, molecular discovery, computer vision, and a data science-based online platform. The company monetizes all products on a direct-to-consumer basis and has no wholesale exposure. ODD has scaled their business quickly, achieving greater than 20% operating margins while still growing their revenue base by greater than 20% to an estimated $800 million in 2025. |
| PHR | PHR provides a SaaS-based platform that automates patient intake, payments, and clinical data for healthcare organizations. The stock declined in the fourth quarter following the release of fiscal third-quarter results. While PHR exceeded estimates for both revenue and earnings, the company provided forward revenue guidance that was viewed as conservative by investors, prompting valuation compression. Phreesia, Inc. (PHR) also struggled in the quarter on back of more conservative forward guidance provided in their third quarter results, though we were encouraged by their improving profitability and expanding network of clients. |
| PL | Top 3 contributors to absolute performance: ATEC, PL, AGX |
| POOL | Pool Corp. distributes swimming pool supplies, equipment, and accessories. The industry remains range-bound, with limited catalysts and sluggish trends in new-home sales and construction. We liquidated the position and redeployed the proceeds into other areas with better growth prospects. Pool sank by -25% while held in the quarter. |
| RBC | RBC Bearings, Inc. (RBC) manufactures engineered precision bearings and related products for customers in the aerospace, defense, and industrial markets. It is a market leader with a strong reputation for technical capabilities, product quality, and on-time delivery. RBC outperformed in 4Q as its quarterly results beat consensus estimates on both revenue and EPS. Its Aerospace and Defense business (A&D, 44% of total revenue) was particularly strong, essentially 'firing on all cylinders.' Management expects strong growth in its A&D backlog and is in the process of adding capacity to meet demand. Growth in its Industrial business (56% of total revenue) remains sluggish, but management has significantly improved the profit margins of this business and is now in the process of implementing growth initiatives. We continue to like RBC's leadership team, well-established strategic playbook, as well as its opportunities for growth and capital deployment. |
| RGEN | Other strong performers in the quarter, primarily driven by strong earnings results, included Repligen |
| ROAD | ROAD is a vertically integrated civil infrastructure company constructing roadways and highways across the Sunbelt. The stock underperformed during the quarter following the release of fiscal fourth-quarter results, where earnings per share missed analyst estimates. |
| ROL | HEICO Corp. (HEI.A), IDEXX Laboratories, Inc. (IDXX) and Rollins, Inc. (ROL) were the three largest contributors to portfolio returns for the year. |
| ROP | After a decade-long partnership with Roper Technologies, we have made a strategic decision to exit our position. Our decision to sell was based on three factors. Firstly, Roper's organic growth rates have begun to lag its pure-play software peers. Secondly, we believe many of these businesses are approaching market saturation, which limits their future growth prospects. Lastly, the valuation no longer provides an attractive margin of safety given the first two challenges. |
| SPSC | SPSC reported a more muted near-term business outlook. Whereas there are certainly some environmental issues we think are temporary, we discovered recently that management made a poor acquisition. As a result, an activist has targeted the firm. We continue to believe the business is advantaged and see multiple avenues for value creation. |
| STVN | Pulling back by -22% was Stevanato Group, which manufactures glass packaging for syringes, autoinjectors, and other pharmaceutical needs. Recent revenues and earnings each exceeded expectations, though management was conservative and merely reaffirmed its guidance for the balance of its fiscal year. There may have been some advanced purchasing from customers, though Stevanato's core business grew well, and we added to our position on the weakness. |
| TKNO | Alpha Teknova (TKNO) was the largest detractor in our long book during the fourth quarter. Alpha Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. One of our favorite archetypes is companies that make the 'picks & shovels' of their industry. Alpha Teknova doesn't invent new medicines or vaccines, but it provides the tools like reagents and lab supplies for over 3,000 biotech customers to grow cells, mix chemical reactions, and run experiments. We believe the beauty of its business model is that Alpha Teknova's products generate recurring revenues with high switching costs since customers do not want to refile technical paperwork with the FDA on their drug development programs. Unfortunately, the company has faced macro headwinds, including a multi-year pandemic hangover, a poor biotech funding environment, and concerns about government and academic spending priorities, all of which have caused customer caution. Based on our analysis, we believe Alpha Teknova's recurring revenue model and end‑market positioning offer compelling upside potential as industry conditions normalize. |
| TREX | TREX Company, a leader in composite decking, was our biggest laggard in Industrials during the fourth quarter, as an increasingly competitive environment and weaker end-market trends led to poor Q3 results. TREX saw business fall off after Labor Day, which is inconsistent with results from other peers and surveys. It was quite surprising and may be a function of its higher DIY business. Regardless, this contradicts our thesis, so we exited the position. |
| TRNS | while Transcat, Inc. (TRNS) saw persistent organic service revenue weakness and margin compression following a series of acquisitions which weighed on profitability and investor sentiment. |
| TYL | TYL lagged in the quarter as investor preference shifted away from software names. While the company's long-term fundamentals and recurring revenue model remain intact, near-term growth visibility and valuation considerations weighed on relative performance. |
| UTI | Top 3 detractors to absolute performance: UTI, INOD, AMSC |
| VCEL | Vericel is a medical device company specializing in cartilage repair and burn care. VCEL's autologous cartilage repair product is differentiated and value-added for younger patients with knee cartilage defects of 2-4 cm. The company recently swung to profitability, and we see margin expansion as revenue ramps. Our intrinsic value estimate is $50 per share. |
| VEEV | Veeva Systems Inc. provides industry cloud solutions to the global life sciences industry. The company delivered solid fiscal third-quarter results and issued guidance above the Street. Veeva management reiterated confidence in achieving its 2030 financial targets, maintaining that the current focus on competitive dynamics with Salesforce.com in the customer relationship management (CRM) market (20% of Veeva's total revenues) does not undermine its long-term trajectory. Despite these positives, the stock sold off by -25% on competitive concerns in the CRM market as Veeva projected lower Vault CRM customer versus its initial expectations. |
| VERX | Vertex detracted from relative quarterly performance |
| VRSK | From a stock selection perspective, our positions in Verisk Analytics, Inc. (VRSK) and Watsco, Inc. (WSO) were the biggest laggards. |
| WCN | Our lone position in Utilities, Waste Connections, Inc. (WCN), was flat for the quarter but the stability of the company's earnings and cash flows provided the downside capture we've come to expect. |
| WLDN | Willdan Group, Inc. (WLDN) posted a full year total return of 172%, successfully capitalizing on surging demand for energy efficiency and grid modernization services, particularly from the AI-driven data center market and large government contracts. |
| WSO | Relative weakness was also driven by Watsco amid softer HVAC trends |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||